Keeps Biopharma Inc.

As of June 30, 2026, Keeps Biopharma Inc. carries a market capitalization of 119.06B, placing it among publicly traded companies globally. Its enterprise value stands at 202.43B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Keeps Biopharma Inc.'s next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Keeps Biopharma Inc. has 20.08M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.54, and the price-to-book ratio stands at 1.90.

As of June 30, 2026, Keeps Biopharma Inc. trades at an EV/EBITDA multiple of 97.93 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.92 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 202.43B versus a market cap of 119.06B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Keeps Biopharma Inc. maintains a current ratio of 1.06, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 119.60, indicating elevated leverage, while an interest coverage ratio of 0.52 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Keeps Biopharma Inc. posted a negative return on equity (ROE) of -18.01, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -5.55, reflecting losses generated across the asset base. The company generates approximately 8.17B in revenue per employee across its workforce of 27.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 7.04 indicates how many times Keeps Biopharma Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Keeps Biopharma Inc. recorded an income tax benefit of -708.91M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -13.72B and -12.34B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Keeps Biopharma Inc.'s stock has declined approximately 41.96% over the past 52 weeks. The 50-day moving average sits at 6,013.40, while the 200-day moving average is 7,262.40.

Over the twelve months ended June 30, 2026, Keeps Biopharma Inc. generated 220.48B in revenue and converted that into -12.34B in net income, yielding earnings per share of -648.41. EBITDA reached 2.07B, while operating income came in at -598.90M.

As of June 30, 2026, Keeps Biopharma Inc. holds 28.99B in cash and equivalents against 95.26B in total debt, resulting in a net debt position of 83.02B. Total book value stands at 62.56B, with working capital of 6.47B providing operational flexibility.

Keeps Biopharma Inc. produced -11.58B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -33.90B in capital expenditures, free cash flow totaled -45.48B - equivalent to -2,265.60 per share.

Over the twelve months ended June 30, 2026, Keeps Biopharma Inc. posted a gross margin of 17.94, reflecting its pricing power and cost economics. The operating margin of -0.27 and net profit margin of -5.60 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -38.21: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -11.68, meaning Keeps Biopharma Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Keeps Biopharma Inc.'s most recent stock split took place on May 20, 2020 with a 1:3 split ratio.

As of June 30, 2026, Keeps Biopharma Inc. has an Altman Z-Score of 1.66, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.